

Achillion Pharmaceuticals

Pharma & biotech

24 April 2014

Moving towards an all-oral combination

Achillion holds the promise of developing an all-oral HCV regimen that can be competitive in the evolving HCV treatment landscape. It is the only small-cap biotech company with HCV drug candidates in three key classes – NS5A, nucleotide NS5B polymerase and protease inhibitors. Early pre- and clinical data for these candidates demonstrated strong potency and favourable drug profiles. Further Phase II clinical trials would provide efficacy data for various combinations, potentially leading to partnerships. Achillion is funded until 2016, after critical Phase II combination data become available: positive data should be a major value inflection point.

Creating a competitive combination HCV regimen

Gilead, the leader in HCV therapy, has developed an oral, ribavirin (RBV)-free NS5B + NS5A inhibitor regimen (sofosbuvir + ledipasvir) that achieved >90% cure rate in genotype 1 treatment-naïve patients with only eight weeks of treatment. Achillion's NS5A inhibitor, ACH-3102, and NS5B inhibitor, ACH-3422, have shown equal or better potency in preclinical and clinical studies so far. Adding ACH-2684, a potent protease inhibitor (PI), Achillion has what it takes to create a HCV regimen that matches Gilead's and could potentially shorten treatment duration to six weeks.

Key triple combination efficacy data in 2015

A Phase II all-oral combination trial of ACH-3422 (NS5B) and ACH-3102 (NS5A) ± ACH-2684 (PI) could start in early 2015, potentially generating efficacy (cure rate) data later in the year. If the data match that of Gilead's sofosbuvir (NS5B) + ledipasvir (NS5A) combination, Achillion (or together with a partner) could advance its regimens into Phase III in early 2016, leading to potential approval and launch in 2017/18. Key Phase II efficacy data would be a major value driver given the high correlation between Phase II and III results for HCV drugs.

Valuation: EV of \$176m

Achillion's modest EV of c \$176m, relative to another HCV company, Idenix (EV of c \$743m with three HCV drugs of two classes in Phase I and II trials), reflects the market's concern about sovalprevir's clinical hold and its possible implication on ACH-2684. Achillion is preparing a complete response package addressing its PI, sovalprevir, which was placed on clinical hold in July 2013 due to liver enzyme elevation in a Phase I drug-drug interaction study. An FDA decision, potentially by end-H114, on the lift of the clinical hold would be a major near-term stock catalyst and would enable sovalprevir development to resume.

Consensus estimates

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/12	2.6	(47.1)	(0.64)	0.0	N/A	N/A
12/13	0.0	(58.9)	(0.63)	0.0	N/A	N/A
12/14e	0.0	(75.2)	(0.77)	0.0	N/A	N/A
12/15e	47.0	(83.3)	(0.90)	0.0	N/A	N/A

Source: Bloomberg

Price **\$3.08**
Market cap **\$298m**

Share price graph



Share details

Code	ACHN
Listing	NASDAQ
Shares in issue	96.8m

Business description

Achillion is a US biotech company focused on infectious disease, particularly chronic hepatitis C (HCV). ACH-3102, an NS5A inhibitor, is in a Phase II HCV trial. Other HCV drug candidates include ACH-2684, a protease inhibitor (PI) in Phase I and ACH-3422, a nucleotide NS5B polymerase inhibitor, in pre-IND testing. Another PI, sovalprevir, which is in an ongoing Phase II trial (study 007), is currently on clinical hold meaning no new trials can be initiated.

Bull

- Ribavirin (RBV)-free anti-HCV regimen has blockbuster potential.
- Could attract a strategic partner or buyer.
- \$158m of cash and cash equivalents at end of 2013, sufficient until 2016.

Bear

- Behind in the RBV-free anti-HCV regimen race.
- Sovalprevir on clinical hold since July 2013.
- Additional cash needed without partner.

Analysts

Jason Y Zhang, PhD	+ 646 653 7027
Lala Gregorek	+44 (0)20 3681 2527

healthcare@edisongroup.com

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2014 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Achillion Pharmaceuticals and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2013]. "FTSE(r)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.